Too funny to imagine "grey sheets" given the top-rated and award winning management and BOD team with Mr. Astrue, Dr. Langer, and other top researchers. Grey sheets are reserved for chiscams of which this company has no similarity, that characterization is completely inappropriate and doesn't fool anyone.
If you scrape away all of today's events, from the admitted shortseller's negative so-called "research" article together with a well-coordinated shortselling shock and awe campaign run simultaneously, then all that is left in terms of REAL DEVELOPMENTS affecting the company over the last 30 days is (1) a corporate announcement that NVIV had to delay uplisting due to corporate governance issues (so what company doesn't have to make some minor changes to uplist and what company uplists in 60 days???), and (2), today's well-received news of the replacement of the joint CEO/CFO with two well-qualified individuals holding separate titles. Clearly, Frank was an overzealous CEO who was great as a founder and idea man to get things started, but over time many investors have grown weary with his style, and think it is now better for the company's future to let another person who is a very experienced biotech CEO manage product launch, clinical trials, and FDA coordination, as well as being responsible for making news releases and PR videos that are less of marketing material and more factual-based, in-line with what you would expect to see produced by a big board biotech.
AI
